

ABT-737

ABT-737 is a small molecule BH3 mimetic inhibitor of the anti-apoptotic members of the BCL-2 family, selective for BCL-2, BCL-XL, and BCL-W (EC50=78.7, 30.3, and 197.8nM, respectively). Developed by Abbvie, it failed in clinical trials due to toxicity issues, but was proven efficacious with various radiation therapies in triggering apoptosis in cancer cells and xenografts.

Materials Provided

| | |
|---------------------------|--------------------------|
| Catalog Number: | 92-1151 |
| Quantity Supplied: | 1 vial(s), 5 mg per vial |

Description

DiscoverX control ligands have been functionally tested and validated for optimal use with all cell line targets and Assay Ready kits.

Product Information

| | |
|--------------------------|---|
| Molecular Weight: | 813.43 g/mol |
| Source: | Synthetic |
| Purity: | ≥ 99% |
| Endotoxin Level: | N/A |
| Formulation: | N/A |
| Storage: | ≤ -20°C Please avoid multiple freeze/thaw cycles. |

Reagent Preparation

To avoid condensation, equilibrate the vial to ambient temperature before opening.

| | |
|--------------------------------|----------|
| Stock Concentration: | 10 mM |
| Reconstitution Volume: | 0.615 mL |
| Reconstitution Solvent: | DMSO |

For Research Use Only

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com
Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com
General product information: www.discoverx.com